Enanta Pharmaceuticals Financial Results
Enanta Pharmaceuticals reported fiscal fourth quarter 2026 revenue of $12.9 million and a net loss of $28.3 million, driven by royalty revenue from AbbVie's HCV regimen. The company highlighted clinical progress in its RSV and immunology pipelines, including the completion of enrollment for its Phase 2b LOTUS trial. Enanta also announced the planned retirement of CEO Jay R. Luly by February 2027.
- Counterparty
- AbbVie
“During fiscal 2026 we made significant progress across our virology and immunology portfolios. In RSV, we completed enrollment in LOTUS, a Phase 2b trial of zelicapavir in pediatric patients, with topline data expected in the first quarter of 2027. We also began dosing patients in RESOLVE, a Phase 2b/3 trial of zelicapavir in adults at high risk of severe disease and anticipate reporting data from the Phase 2b portion in 2027.”
Jay R. Luly, Ph.D., President and Chief Executive Officer
“In parallel, we are advancing a growing immunology portfolio focused on developing best-in-class oral medicines that have the potential to raise the standard of care across multiple immune-mediated diseases. We expect to complete dosing in the EDP-978 Phase 1 trial by year-end 2026 and now plan to report data in the first quarter of 2027.”
Jay R. Luly, Ph.D., President and Chief Executive Officer